TD Cowen initiated coverage on Sionna Therapeutics
$SION
Biotechnology: Pharmaceutical Preparations
Health Care
TD Cowen initiated coverage of Sionna Therapeutics with a rating of Buy
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/1/2025 | $24.00 | Sector Perform → Underperform | RBC Capital Mkts |
| 11/19/2025 | $50.00 | Buy | BTIG Research |
| 9/3/2025 | $45.00 | Strong Buy | Raymond James |
| 9/3/2025 | $22.00 | Sector Perform | RBC Capital Mkts |
| 3/4/2025 | Buy | TD Cowen | |
| 3/4/2025 | $32.00 | Buy | Stifel |
| 3/4/2025 | $45.00 | Buy | Guggenheim |
4 - Sionna Therapeutics, Inc. (0002036042) (Issuer)
4 - Sionna Therapeutics, Inc. (0002036042) (Issuer)
4 - Sionna Therapeutics, Inc. (0002036042) (Issuer)
144 - Sionna Therapeutics, Inc. (0002036042) (Subject)
144 - Sionna Therapeutics, Inc. (0002036042) (Subject)
144 - Sionna Therapeutics, Inc. (0002036042) (Subject)
RBC Capital Mkts downgraded Sionna Therapeutics from Sector Perform to Underperform and set a new price target of $24.00
BTIG Research initiated coverage of Sionna Therapeutics with a rating of Buy and set a new price target of $50.00
Raymond James initiated coverage of Sionna Therapeutics with a rating of Strong Buy and set a new price target of $45.00
4 - Sionna Therapeutics, Inc. (0002036042) (Issuer)
4 - Sionna Therapeutics, Inc. (0002036042) (Issuer)
WALTHAM, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (NASDAQ:SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced that management will present at the Guggenheim Securities Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11th, 2026 at 2:00 p.m. ET. A live webcast of the presentation will be available under the "Events" page within the Investors section of Sionna's website at https://investors.sionnatx.com/. A replay will also
WALTHAM, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (NASDAQ:SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced that management will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13th, 2026 at 9:45 a.m. PT/12:45 p.m. ET. A live webcast of the presentation will be available under the "Events" page within the Investors section of Sionna's website at https://investors.sionnatx.com/. A replay will also be
WALTHAM, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (NASDAQ:SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced that management will participate in fireside chats at the following upcoming investor events: 8th Annual Evercore Healthcare Conference on Wednesday, December 3rd, 2025, at 12:30 p.m. ET; andCiti 2025 Global Healthcare Conference on Thursday, December 4th, 2025, at 9:45 a.m. ET Live webcasts of the presentations will be avail
WALTHAM, Mass., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (NASDAQ:SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced the appointment of Caroline Stark Beer, MBA, as its Chief Business Officer (CBO). "We are delighted to welcome Caroline to our executive team at such a pivotal stage for Sionna," said Mike Cloonan, President and Chief Executive Officer of Sionna. "Caroline's exceptional experience, leadership, and value creation mindset will
SION-719 and SION-451 were generally well tolerated and achieved desired pharmacokinetic targets that reinforce their potential as either an add-on to standard of care or in a Sionna dual combination Sionna plans to advance SION-719 to a Phase 2a proof-of-concept add-on to standard of care trial in cystic fibrosis patients, and SION-451 to a Phase 1 healthy volunteer dual combination trial Next trials to initiate in the second half of 2025 with topline data expected in mid-2026 Sionna to hold a conference call today at 8:00 a.m. ET WALTHAM, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (NASDAQ:SION), a clinical-stage biopharmaceutical company on a mission to revo